Haisco Pharmaceutical Group (002653) Q3 2024 earnings summary

Executive summary

• Revenue for the first nine months reached ¥2.75 billion, up 15.41% year-over-year.

• Net profit attributable to shareholders was ¥381.82 million, a 90.20% increase year-over-year.

• Significant non-recurring gains included asset disposals and government subsidies.

Financial highlights

• Q3 revenue was ¥1.06 billion, up 4.96% compared to the same quarter last year.

• Q3 net profit attributable to shareholders was ¥217.10 million, up 72.76% year-over-year.

• Operating cash flow for the first nine months was ¥195.92 million, up 47.83% year-over-year.

• Basic and diluted EPS for the first nine months were ¥0.3409, up 88.13% year-over-year.

Outlook and guidance

• Increased R&D investment and successful launches of new products are expected to support future growth.